Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Statins and demyelination.

M S Weber1, S S Zamvil

  • 1Department of Neurology, University of California, San Francisco, 513 Parnassus Avenue, S-268, San Francisco, CA 94143-0435, USA.

Current Topics in Microbiology and Immunology
|January 29, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evidence for the Collective Nature of Radial Flow in Pb+Pb Collisions with the ATLAS Detector.

Physical review letters·2026
Same author

Evidence for the Dimuon Decay of the Higgs Boson in pp Collisions with the ATLAS Detector.

Physical review letters·2025
Same author

Evidence for Longitudinally Polarized W Bosons in the Electroweak Production of Same-Sign W Boson Pairs in Association with Two Jets in pp Collisions at sqrt[s]=13  TeV with the ATLAS Detector.

Physical review letters·2025
Same author

Observation of tt[over ¯] Production in Pb+Pb Collisions at sqrt[s_{NN}]=5.02  TeV with the ATLAS Detector.

Physical review letters·2025
Same author

Search for Dark Matter Produced in Association with a Dark Higgs Boson in the bb[over ¯] Final State Using pp Collisions at sqrt[s]=13  TeV with the ATLAS Detector.

Physical review letters·2025
Same author

Search for Magnetic Monopole Pair Production in Ultraperipheral Pb+Pb Collisions at sqrt[s_{NN}]=5.36  TeV with the ATLAS Detector at the LHC.

Physical review letters·2025
Same journal

Resolution Biology in Soft Tissue Joint Disease.

Current topics in microbiology and immunology·2026
Same journal

A 25+ Year Journey on Yeast-Regulated Cell Death Research.

Current topics in microbiology and immunology·2026
Same journal

Adoptive T-Cell Immunotherapy.

Current topics in microbiology and immunology·2026
Same journal

Resolution Pharmacology Targeting the Melanocortin System.

Current topics in microbiology and immunology·2026
Same journal

Resolution of Skeletal Muscle Inflammation: Role of Specialized Pro-resolving Lipid Mediators in the Recovery from Exercise, Injury, and Disease.

Current topics in microbiology and immunology·2026
Same journal

Epstein-Barr Virus: From the Detection of Sequence Polymorphisms to the Recognition of Viral Strains.

Current topics in microbiology and immunology·2026
See all related articles

Statins, used for cholesterol, show promise for autoimmune diseases like multiple sclerosis (MS). They modulate the immune system by inhibiting protein prenylation, potentially benefiting MS patients.

Area of Science:

  • Immunology
  • Pharmacology
  • Neuroscience

Background:

  • Statins inhibit HMG-CoA reductase, widely used for lowering cholesterol and reducing cardiovascular risk.
  • Statins possess pleiotropic immunomodulatory effects, suggesting therapeutic potential for autoimmune disorders.
  • These immune effects appear independent of lipid-lowering, mediated by inhibiting protein prenylation.

Purpose of the Study:

  • To investigate the therapeutic potential of statins in autoimmune diseases, specifically multiple sclerosis (MS).
  • To evaluate the immunomodulatory mechanisms of statins beyond their lipid-lowering effects.

Main Methods:

  • Utilized experimental autoimmune encephalomyelitis (EAE), a murine model for MS.
  • Administered statins to EAE models to assess therapeutic benefits.

Related Experiment Videos

  • Investigated the role of protein prenylation inhibition in statin's immunomodulatory actions.

    • Main Results:

    • Statins demonstrated the ability to reverse established paralysis in EAE models.
    • Statins showed synergistic effects when combined with existing MS therapies.
    • Evidence suggests statins alter immune function via inhibition of protein prenylation.

    Conclusions:

    • Statins exhibit significant therapeutic potential in experimental models of MS.
    • The immunomodulatory effects of statins, independent of lipid lowering, are crucial for their efficacy in autoimmune conditions.
    • Encouraging results from EAE studies have led to clinical trials of statins in human MS patients.